Published in BJU Int on September 08, 2008
Chemotherapy-induced weakness and fatigue in skeletal muscle: the role of oxidative stress. Antioxid Redox Signal (2011) 1.34
Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol (2009) 0.91
Silibinin can induce differentiation as well as enhance vitamin D3-induced differentiation of human AML cells ex vivo and regulates the levels of differentiation-related transcription factors. Hematol Oncol (2010) 0.91
Vitamin d: are we ready to supplement for breast cancer prevention and treatment? ISRN Oncol (2013) 0.83
The efficacy of calcitriol therapy in the management of bone loss and fractures: a qualitative review. Osteoporos Int (2009) 0.82
Vitamin d: pharmacokinetics and safety when used in conjunction with the pharmaceutical drugs used in cancer patients: a systematic review. Cancers (Basel) (2013) 0.80
Vitamin D, intermediary metabolism and prostate cancer tumor progression. Front Physiol (2014) 0.79
Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions. J Cancer (2016) 0.77
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol (2004) 2.92
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol (2012) 2.48
Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol (2008) 2.47
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res (2010) 2.42
Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A (2003) 2.31
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol (2003) 2.07
Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol (2006) 1.98
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer (2008) 1.92
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol (2006) 1.92
Statins and prostate cancer risk: a case-control study. Am J Epidemiol (2005) 1.90
Improved detection of prostate cancer using classification and regression tree analysis. J Clin Oncol (2005) 1.85
Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res (2003) 1.81
Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol (2012) 1.76
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol (2007) 1.75
Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology (2006) 1.75
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol (2012) 1.66
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology (2010) 1.65
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Lower urinary tract symptoms increase the risk of falls in older men. BJU Int (2009) 1.53
EphB4 expression and biological significance in prostate cancer. Cancer Res (2005) 1.53
Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer (2005) 1.49
A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med (2011) 1.48
Advanced penile carcinoma. J Urol (2003) 1.47
Overcoming autopsy barriers in pediatric cancer research. Pediatr Blood Cancer (2012) 1.47
Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol (2006) 1.46
Interest in physician-assisted suicide among Oregon cancer patients. J Clin Ethics (2006) 1.45
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol (2007) 1.41
Treatment of Nonmetastatic Castration-Resistant Prostate Cancer. Oncology (Williston Park) (2016) 1.38
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer (2011) 1.38
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol (2012) 1.37
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 1.37
Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging (2012) 1.34
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group. J Clin Oncol (2007) 1.32
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.29
Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol (2002) 1.28
Acupuncture for hot flashes in patients with prostate cancer. Urology (2010) 1.27
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs (2009) 1.26
HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia. J Biol Chem (2011) 1.25
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer (2007) 1.23
Intraoperative renal cell carcinoma tumor embolization to the right atrium: incidental diagnosis by transesophageal echocardiography. Anesth Analg (2006) 1.23
Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol (2009) 1.21
Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol (2004) 1.20
Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med (2012) 1.19
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer (2009) 1.17
Testosterone loss and estradiol administration modify memory in men. J Urol (2006) 1.16
Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer (2005) 1.15
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate (2010) 1.14
Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery (2003) 1.12
Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol (2004) 1.11
One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer. Psychiatr Serv (2011) 1.11
Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases. Radiology (2015) 1.10
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Cancer (2008) 1.10
Patient-physician disagreement regarding performance status is associated with worse survivorship in patients with advanced cancer. Cancer (2008) 1.08
Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int (2011) 1.08
Phase II study of abarelix depot for androgen independent prostate cancer progression during gonadotropin-releasing hormone agonist therapy. J Urol (2003) 1.07
Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene (2003) 1.06
Gene expression profiling of renal medullary carcinoma: potential clinical relevance. Cancer (2004) 1.06
Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2004) 1.06
Both beta-actin and GAPDH are useful reference genes for normalization of quantitative RT-PCR in human FFPE tissue samples of prostate cancer. Prostate (2008) 1.04
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 1.04
Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol (2004) 1.03
Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst (2006) 1.03
Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med (2013) 1.02
C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol (2010) 1.02
SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res (2003) 1.02
The iroquois homeobox gene 5 is regulated by 1,25-dihydroxyvitamin D3 in human prostate cancer and regulates apoptosis and the cell cycle in LNCaP prostate cancer cells. Clin Cancer Res (2008) 1.01
ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res (2010) 1.01